Cytokinetics Fleshes Out Its Skeletal Business With New Partner Astellas
This article was originally published in The Pink Sheet Daily
Executive Summary
Cytokinetics and Astellas Pharma will develop and commercialize new drugs for muscle weakness under a two-year research collaboration. Cytokinetics out-licensed rights to the Phase I drug CK-2127107, but holds onto rights to its later-stage skeletal muscle activator tirasemtiv.
You may also be interested in...
Deals Of The Week Looks At How Amgen’s Global Expansion Affects Partnering
Plus perspectives on AstraZeneca/Pearl Therapeutics, Xenon/Isis, Questcor/Novartis, BMS/Simcere and more.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.